Wang Dazhi1,2, Zhang Mengxi1, Chen Fufeng2, Yan Meixing1. 1. Qingdao Municipal Hospital, School of Medicine, Qingdao University, No. 5 Donghai Middle Road, Qingdao, Shandong Province, 266071, China. 2. School of Basic Medicine, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, China.
Abstract
AIM: To investigate the expression of TRIP13 in multiple tumors and to evaluate the relationship between TRIP13 and survival of cancer patients. MATERIALS & METHODS: Sample expression profiles were downloaded from the gene expression omnibus database. Correlation between TRIP13 expression and clinicopathological features was analyzed by χ2 test. Patient survival was evaluated by Kaplan-Meier analysis. RESULTS: TRIP13 expression was upregulated in 12 cancer types; it significantly correlated with multiple clinicopathological features of breast, liver and lung cancer. High TRIP13 expression indicated poor prognosis of patients with breast, liver, gastric and lung cancer. CONCLUSION: TRIP13 is highly expressed in multiple tumors and may be used as a potential prognostic marker and therapeutic target.
AIM: To investigate the expression of TRIP13 in multiple tumors and to evaluate the relationship between TRIP13 and survival of cancerpatients. MATERIALS & METHODS: Sample expression profiles were downloaded from the gene expression omnibus database. Correlation between TRIP13 expression and clinicopathological features was analyzed by χ2 test. Patient survival was evaluated by Kaplan-Meier analysis. RESULTS:TRIP13 expression was upregulated in 12 cancer types; it significantly correlated with multiple clinicopathological features of breast, liver and lung cancer. High TRIP13 expression indicated poor prognosis of patients with breast, liver, gastric and lung cancer. CONCLUSION:TRIP13 is highly expressed in multiple tumors and may be used as a potential prognostic marker and therapeutic target.
Entities:
Keywords:
cancer biomarkers; poor prognosis; thyroid hormone receptor-interacting protein 13